February 6, 2024 10:23 AM EST
News Briefing

Im­munome buys desmoid tu­mor as­set; UK looks in­to Ther­mo Fish­er-Olink deal; Kyver­na's up­sized IPO

Jaimy Lee

Deputy Editor

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Plus, news about At­tralus, Sang­amo, Mithra, NeOnc, 4D Mol­e­c­u­lar Ther­a­peu­tics and Im­mix Bio­phar­ma:

Im­munome buys Ay­ala’s desmoid tu­mor as­set: The biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times